{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T18:40:52Z","timestamp":1792435252127,"version":"4.5.0"},"reference-count":34,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Liver function monitoring remains a cornerstone of safety surveillance during methotrexate (MTX) therapy for rheumatoid arthritis. Traditionally, monitoring has focused on hepatitis B virus (HBV) reactivation and chronic MTX hepatotoxicity. Because HBV persists in hepatocytes as covalently closed circular DNA even after apparent clinical resolution of infection, all individuals with previous HBV exposure remain at risk of viral reactivation. Accordingly, screening for previous HBV infection before initiating MTX is essential, and regular monitoring of HBV DNA should be considered in patients with resolved or chronic HBV infection. Close collaboration with hepatology specialists is required to ensure timely initiation of nucleos(t)ide analogue therapy when indicated. In contrast, the conventional concept of chronic MTX-induced hepatotoxicity has been increasingly challenged. Recent studies employing non-invasive fibrosis assessment tools have demonstrated little or no association between cumulative MTX dose or treatment duration and the progression of liver fibrosis. These findings suggest that severe chronic liver injury caused solely by MTX is uncommon and that the hepatotoxic potential of MTX may have been substantially overestimated. Metabolic dysfunction-associated steatotic liver disease has emerged as the leading chronic liver disease worldwide and appears to be at least as prevalent among patients with rheumatoid arthritis than in the general population. Therefore, evaluation and management of metabolic dysfunction-associated steatotic liver disease should be considered as part of routine clinical care for patients with rheumatoid arthritis. Because liver fibrosis is the most important determinant of long-term hepatic outcomes, monitoring strategies should incorporate fibrosis assessment using non-invasive tools such as the fibrosis-4 index and elastography-based liver stiffness measurement.<\/jats:p>","DOI":"10.1093\/mr\/roag085","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T12:03:36Z","timestamp":1790769816000},"source":"Crossref","is-referenced-by-count":0,"title":["Revisiting liver monitoring during methotrexate therapy in rheumatoid arthritis: Implications of HBV reactivation, MASLD, and non-invasive fibrosis assessment"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5647-8159","authenticated-orcid":false,"given":"Ryuji","family":"Koike","sequence":"first","affiliation":[{"name":"Health Science Research and Development Center, Institute of Science Tokyo Hospital , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Yamanishi","sequence":"additional","affiliation":[{"name":"Hiroshima Rheumatology Clinic , Hiroshima ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mie","family":"Fusama","sequence":"additional","affiliation":[{"name":"Health Sciences Department of Nursing, Kansai University of International Studies , Hyogo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeru","family":"Iwata","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Wakayama Medical University , Wakayama ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Tada","sequence":"additional","affiliation":[{"name":"Department of Orthopedic Surgery, Osaka City General Hospital , Osaka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruka","family":"Tsuchiya","sequence":"additional","affiliation":[{"name":"Department of Allergy and Rheumatology, The University of Tokyo Hospital , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunihiro","family":"Yamaoka","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Kitasato University , Kanagawa ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideto","family":"Kameda","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Toho University , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,10,1]]},"reference":[{"key":"2026101914214926200_ref1","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1080\/21505594.2022.2028483","article-title":"Pathogenicity and virulence of hepatitis B virus","volume":"13","author":"Chuang","year":"2022","journal-title":"Virulence"},{"key":"2026101914214926200_ref2","first-page":"99","volume-title":"Clinical Practice Guidelines for Hepatitis B","author":"The Japan Society of Hepatology Subcommittee of the Guideline for the management of viral hepatitis (eds.)","year":"2022","edition":"4"},{"key":"2026101914214926200_ref3","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1002\/acr.24596","article-title":"2021 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis","volume":"73","author":"Fraenkel","year":"2021","journal-title":"Arthritis Care Res"},{"key":"2026101914214926200_ref4","doi-asserted-by":"crossref","DOI":"10.1016\/j.tox.2021.152840","article-title":"Hepatotoxic potentials of methotrexate: understanding the possible toxicological molecular mechanisms","volume":"458","author":"Ezhilarasan","year":"2021","journal-title":"Toxicology"},{"key":"2026101914214926200_ref5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/mr\/road098","article-title":"Japan College of Rheumatology guidance for the use of methotrexate in patients with rheumatoid arthritis: secondary publication","volume":"34","author":"Kameda","year":"2024","journal-title":"Mod Rheumatol"},{"key":"2026101914214926200_ref6","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1046\/j.1365-2036.2004.01819.x","article-title":"Monitoring methotrexate-induced hepatic fibrosis in patients with psoriasis: are serial liver biopsies justified?","volume":"19","author":"Aithal","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"2026101914214926200_ref7","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.cld.2013.07.012","article-title":"Drug-induced steatohepatitis","volume":"17","author":"Patel","year":"2013","journal-title":"Clin Liver Dis"},{"key":"2026101914214926200_ref8","doi-asserted-by":"crossref","first-page":"5203","DOI":"10.3390\/ijms25105203","article-title":"Drug-induced fatty liver disease (DIFLD): a comprehensive analysis of clinical, biochemical, and histopathological data for mechanisms identification and consistency with current adverse outcome pathways","volume":"25","author":"L\u00f3pez-Pascual","year":"2024","journal-title":"Int J Mol Sci"},{"key":"2026101914214926200_ref9","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0190-9622(88)80237-8","article-title":"Methotrexate in psoriasis: revised guidelines","volume":"19","author":"Roenigk","year":"1988","journal-title":"J Am Acad Dermatol"},{"key":"2026101914214926200_ref10","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/j.0954-6820.1973.tb19478.x","article-title":"Fatty liver persisting for up to 33 years","volume":"194","author":"Hilden","year":"1973","journal-title":"Acta Med Scand"},{"key":"2026101914214926200_ref11","first-page":"283","article-title":"Nonalcoholic fatty liver disease","volume":"8","author":"Schaffner","year":"1986","journal-title":"Prog Liver Dis"},{"key":"2026101914214926200_ref12","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety Delphi consensus statement on new fatty liver sidease nomenclature","volume":"79","author":"Rinella","year":"2023","journal-title":"J Hepatol"},{"key":"2026101914214926200_ref13","volume-title":"Evidence-based Clinical Practice Guidelines for Metabolic Dysfunction-Associated Steatotic Liver Disease 2026","author":"The Japanese Society of Gastroenterology, The Japan Society of Hepatology (eds.)","year":"2026","edition":"3"},{"key":"2026101914214926200_ref14","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.1016\/j.jhep.2023.08.026","article-title":"99% of patients with NAFLD meet MASLD criteria and natural history is therefore identical","volume":"80","author":"Hagstr\u00f6m","year":"2024","journal-title":"J Hepatol"},{"key":"2026101914214926200_ref15","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/s41584-022-00883-4","article-title":"Busting the myth of methotrexate chronic hepatotoxicity","volume":"19","author":"Martino","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"2026101914214926200_ref16","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1056\/NEJMra2403308","article-title":"Noninvasive assessment of liver fibrosis","volume":"393","author":"Castera","year":"2025","journal-title":"N Engl J Med"},{"key":"2026101914214926200_ref17","doi-asserted-by":"crossref","first-page":"053","DOI":"10.46497\/ArchRheumatol.2025.10702","article-title":"Disease activity and changes in the fibrosis-4 index in patients with rheumatoid arthritis treated with methotrexate for a short period","volume":"40","author":"Namura","year":"2025","journal-title":"Arch Rheunatol"},{"key":"2026101914214926200_ref18","doi-asserted-by":"crossref","first-page":"150","DOI":"10.55563\/clinexprheumatol\/usddjr","article-title":"Risk of liver fibrosis induced by methotrexate and other rheumatoid arthritis medications according to the Fibrosis-4 index","volume":"40","author":"Avouac","year":"2022","journal-title":"Clin Exp Rheumatol"},{"key":"2026101914214926200_ref19","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.3390\/jcm13071905","article-title":"Repurposing the Fibrosis-4 score in rheumatoid arthritis: data from the ESPOIR cohort","volume":"13","author":"Felten","year":"2024","journal-title":"J Clin Med"},{"key":"2026101914214926200_ref20","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1007\/s10067-025-07364-5","article-title":"Metabolic dysfunction-associated steatotic liver disease and cardiovascular risk factors in rheumatoid arthritis","volume":"44","author":"Saidi","year":"2025","journal-title":"Clin Rheumatol"},{"key":"2026101914214926200_ref21","doi-asserted-by":"crossref","first-page":"5065","DOI":"10.1093\/rheumatology\/keaf263","article-title":"The Fibrosis-4 Index (FIB-4) correlates with cardiovascular risk and insulin resistance in patients with rheumatoid arthritis","volume":"64","author":"Ferraz-Amaro","year":"2025","journal-title":"Rheumatology"},{"key":"2026101914214926200_ref22","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s00296-025-06002-2","article-title":"Rheumatoid arthritis is independently associated with metabolic dysfunction-associated steatotic liver disease: evidence from the paracelsus 10,000 population-based cohort study","volume":"45","author":"Ausserwinkler","year":"2025","journal-title":"Rheumatol Int"},{"key":"2026101914214926200_ref23","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1007\/s00296-025-05987-0","article-title":"Methotrexate and biological therapy are not associated with fatty liver in rheumatoid arthritis-a cross-sectional study","volume":"45","author":"Zeki\u0107","year":"2025","journal-title":"Rheumatol Int"},{"key":"2026101914214926200_ref24","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.jhep.2022.12.034","article-title":"Risk of liver fibrosis associated with long-term methotrexate therapy may be overestimated","volume":"78","author":"Atallah","year":"2023","journal-title":"J Hepatol"},{"key":"2026101914214926200_ref25","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.jhep.2023.02.018","article-title":"Methotrexate-induced liver fibrosis: the end of a long-held belief","volume":"78","author":"Martino","year":"2023","journal-title":"J Hepatol"},{"key":"2026101914214926200_ref26","doi-asserted-by":"crossref","first-page":"699","DOI":"10.4254\/wjh.v15.i5.699","article-title":"Liver steatosis in patients with rheumatoid arthritis treated with methotrexate is associated with body mass index","volume":"15","author":"Castiella","year":"2023","journal-title":"World J Hepatol"},{"key":"2026101914214926200_ref27","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.ajg.2025.06.001","article-title":"Methotrexate induced liver fibrosis is over estimated as assessed by transient elastography, acoustic radiation force impulse and serum markers","volume":"26","author":"Badary","year":"2025","journal-title":"Arab J Gastroenterol"},{"key":"2026101914214926200_ref28","first-page":"3","article-title":"The relationship between dose of methotrexate and incidence of liver fibrosis in patients with rheumatoid arthritis","volume":"63","author":"AkbariRad","year":"2025","journal-title":"Reumatologia"},{"key":"2026101914214926200_ref29","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1007\/s10067-023-06847-7","article-title":"Associated factors with liver fibrosis in rheumatoid arthritis patients treated with methotrexate","volume":"43","author":"Slouma","year":"2024","journal-title":"Clin Rheumatol"},{"key":"2026101914214926200_ref30","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1007\/s10067-024-06896-6","article-title":"Commentary on the factors with liver fibrosis in rheumatoid arthritis patients treated with methotrexate","volume":"43","author":"Chen","year":"2024","journal-title":"Clin Rheumatol"},{"key":"2026101914214926200_ref31","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s40477-023-00843-y","article-title":"Longitudinal assessment of liver fibrosis using ARFI technique does not support increased risk of fibrosis in rheumatoid arthritis patients on methotrexate","volume":"28","author":"Sch\u00e4fer","year":"2025","journal-title":"J Ultrasound"},{"key":"2026101914214926200_ref32","doi-asserted-by":"crossref","first-page":"3605","DOI":"10.1007\/s10067-021-05678-8","article-title":"Prevalence of liver fibrosis by Fibroscan in patients on long-term methotrexate therapy for rheumatoid arthritis","volume":"40","author":"Bafna","year":"2021","journal-title":"Clin Rheumatol"},{"key":"2026101914214926200_ref33","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/1756-185X.13442","article-title":"Association between cumulative methotrexate dose, non-invasive scoring system and hepatic fibrosis detected by Fibroscan in rheumatoid arthritis patients receiving methotrexate","volume":"22","author":"Lertnawapan","year":"2019","journal-title":"Int J Rheum Dis"},{"key":"2026101914214926200_ref34","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/jcu.23847","article-title":"Evaluation of liver parenchyma with shear wave elastography in patients with rheumatoid arthritis receiving disease-modifying antirheumatic drug therapy","volume":"53","author":"Tezcan","year":"2025","journal-title":"J Clin Ultrasound"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mr\/advance-article-pdf\/doi\/10.1093\/mr\/roag085\/71560637\/roag085.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/advance-article-pdf\/doi\/10.1093\/mr\/roag085\/71560637\/roag085.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T18:21:57Z","timestamp":1792434117000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mr\/advance-article\/doi\/10.1093\/mr\/roag085\/8859184"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":34,"URL":"https:\/\/doi.org\/10.1093\/mr\/roag085","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,1]]},"article-number":"roag085"}}